Eli Lilly and Company [NYSE: LLY] gained 1.45% on the last trading session, reaching $145.49 price per share at the time. The company report on November 21, 2020 that Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19.
– Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera.
TORONTO, Nov. 20, 2020 /CNW/ – Health Canada granted authorization, under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, for the use of bamlanivimab (LY-CoV-555) as a treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization, Eli Lilly and Company (NYSE: LLY) announced. This authorization, the second authorization around the world for bamlanivimab, is based on data from BLAZE-1, a randomized, double-blind placebo-controlled phase 2 study in patients with recently diagnosed, mild to moderate COVID-19.
Eli Lilly and Company represents 907.20 million in outstanding shares, while the company has a total market value of $137.18 billion with the latest information. LLY stock price has been found in the range of $142.84 to $147.09.
If compared to the average trading volume of 3.94M shares, LLY reached a trading volume of 5060819 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Eli Lilly and Company [LLY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $165.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Berenberg raised their target price to Hold. The new note on the price target was released on September 29, 2020, representing the official price target for Eli Lilly and Company stock. Previously, the target price had yet another raise to $176, while Morgan Stanley analysts kept a Overweight rating on LLY stock.
The Average True Range (ATR) for Eli Lilly and Company is set at 4.50, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 5.91. The Price to Book ratio for the last quarter was 27.35, with the Price to Cash per share for the same quarter was set at 3.85. Price to Free Cash Flow for LLY in the course of the last twelve months was 49.27 with Quick ratio for the last quarter at 1.10.
Trading performance analysis for LLY stock
Eli Lilly and Company [LLY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.18. With this latest performance, LLY shares gained by 2.71% in over the last four-week period, additionally sinking by -1.67% over the last 6 months – not to mention a rise of 26.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 54.76, with the RSI for the last a single of trading hit 58.66, and the three-weeks RSI is set at 52.19 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 144.83, while it was recorded at 142.17 for the last single week of trading, and 148.80 for the last 200 days.
Eli Lilly and Company [LLY]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Eli Lilly and Company [LLY] shares currently have an operating margin of +25.94 and a Gross Margin at +78.85. Eli Lilly and Company’s Net Margin is presently recorded at +20.78.
Return on Total Capital for LLY is now 27.37, given the latest momentum, and Return on Invested Capital for the company is 24.17. Return on Equity for this stock inclined to 74.59, with Return on Assets sitting at 11.15. When it comes to the capital structure of this company, Eli Lilly and Company [LLY] has a Total Debt to Total Equity ratio set at 610.90. Additionally, LLY Total Debt to Total Capital is recorded at 85.93, with Total Debt to Total Assets ending up at 40.54. Long-Term Debt to Equity for the company is recorded at 548.72, with the Long-Term Debt to Total Capital now at 77.19.
Reflecting on the efficiency of the workforce at the company, Eli Lilly and Company [LLY] managed to generate an average of $137,930 per employee. Receivables Turnover for the company is 3.80 with a Total Asset Turnover recorded at a value of 0.54.Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
Eli Lilly and Company [LLY]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Eli Lilly and Company posted 1.73/share EPS, while the average EPS was predicted by analysts to be reported at 1.52/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 12.28%.
An analysis of insider ownership at Eli Lilly and Company [LLY]
There are presently around $106,807 million, or 79.30% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 111,132,343, which is approximately -0.384% of the company’s market cap and around 11.70% of the total institutional ownership; VANGUARD GROUP INC, holding 69,165,364 shares of the stock with an approximate value of $10.06 billion in LLY stocks shares; and BLACKROCK INC., currently with $8.8 billion in LLY stock with ownership of nearly -3.754% of the company’s market capitalization.
Positions in Eli Lilly and Company stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 759 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 25,786,881 shares. Additionally, 793 investors decreased positions by around 33,957,227 shares, while 335 investors held positions by with 674,375,674 shares. The mentioned changes placed institutional holdings at 734,119,782 shares, according to the latest SEC report filing. LLY stock had 136 new institutional investments in for a total of 4,380,647 shares, while 119 institutional investors sold positions of 1,862,499 shares during the same period.